3E0L705 ICD-10-PCS Code: Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening

Related Codes

Same operation — other Body System / Region

Same table and root operation, differing only in the body system / region character.

3E0G705 — Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening, 3E0H705 — Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening, 3E0J705 — Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening, 3E0K705 — Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening, 3E0M705 — Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening, 3E0N705 — Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening, 3E0P705 — Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening, 3E0Q705 — Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening, +7 more

Same operation — other Approach

Same table and root operation, differing only in the approach character.

3E0L305 — Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach

Same operation — other Qualifier

Same table and root operation, differing only in the qualifier character.

3E0L704 — Introduction of Liquid Brachytherapy Radioisotope into Pleural Cavity, Via Natural or Artificial Opening, 3E0L70M — Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening

Same procedure category (CCSR), other tables

AHRQ's Clinical Classifications Software Refined groups these ICD-10-PCS procedures with this one under Chemotherapy (Administration of Therapeutic Substances); listed here are the members in other PCS tables. Source: Clinical Classifications Software Refined (CCSR), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, November 2025.

XW01318 — Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8, XW01329 — Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9, XW01348 — Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8, XW013L9 — Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9, XW013S9 — Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9, XW03358 — Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8, XW03368 — Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8, XW03378 — Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8, XW03387 — Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7, XW03388 — Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8, XW0338A — Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10, XW0339A — Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10, XW033A7 — Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7, XW033B3 — Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3, XW033B7 — Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7, XW033BA — Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10, XW033C7 — Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7, XW033CA — Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10, XW033G7 — Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7, XW033H7 — Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7, +40 more

Contextual Map

Every relationship of 3E0L705 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.

PCS table

• 3E0[PCS table]— CMS ICD-10-PCS tables
• Administration — Section: Administration[Section]: “Administration”— CMS ICD-10-PCS tables
• Physiological Systems and Anatomical Regions — Body System: Physiological Systems and Anatomical Regions[Body System]: “Physiological Systems and Anatomical Regions”— CMS ICD-10-PCS tables
• Introduction — Operation: Introduction[Operation]: “Introduction”— CMS ICD-10-PCS tables

Clinical classification (CCSR)

• ADM012 — Chemotherapy[CCSR category]: “Chemotherapy — Administration of Therapeutic Substances”— AHRQ CCSR for ICD-10-PCS Procedures (HCUP) · v2026.1

Nearest codes

• 3E09705 — Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening[One axis away]— CMS ICD-10-PCS tables
• 3E0B705 — Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening[One axis away]— CMS ICD-10-PCS tables
• 3E0C705 — Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening[One axis away]— CMS ICD-10-PCS tables
• 3E0D705 — Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening[One axis away]— CMS ICD-10-PCS tables
• 3E0E705 — Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening[One axis away]— CMS ICD-10-PCS tables
• 3E0F705 — Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening[One axis away]— CMS ICD-10-PCS tables
• 3E0G705 — Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening[One axis away]— CMS ICD-10-PCS tables
• 3E0H705 — Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening[One axis away]— CMS ICD-10-PCS tables